Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer
Open Access
- 1 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-14
- https://doi.org/10.1038/s41467-021-21047-0
Abstract
Nanomedicine in combination with immunotherapy offers opportunities to treat cancer in a safe and effective manner; however, remote control of immune response with spatiotemporal precision remains challenging. We herein report a photothermally activatable polymeric pro-nanoagonist (APNA) that is specifically regulated by deep-tissue-penetrating second near-infrared (NIR-II) light for combinational photothermal immunotherapy. APNA is constructed from covalent conjugation of an immunostimulant onto a NIR-II semiconducting transducer through a labile thermo-responsive linker. Upon NIR-II photoirradiation, APNA mediates photothermal effect, which not only triggers tumor ablation and immunogenic cell death but also initiates the cleavage of thermolabile linker to liberate caged agonist for in-situ immune activation in deep solid tumor (8mm). Such controlled immune regulation potentiates systemic antitumor immunity, leading to promoted cytotoxic T lymphocytes and helper T cell infiltration in distal tumor, lung and liver to inhibit cancer metastasis. Thereby, the present work illustrates a generic strategy to prepare pro-immunostimulants for spatiotemporal regulation of cancer nano-immunotherapy. Precise control of immune response remains challenging for cancer immunotherapy. Here, the authors report on photothermally activatable semiconducting polymeric pro-agonist in response to second near-infrared window light for regulated photothermal immunotherapy.This publication has 52 references indexed in Scilit:
- Surface Plasmon Resonance Enhanced Light Absorption and Photothermal Therapy in the Second Near-Infrared WindowJournal of the American Chemical Society, 2014
- A stepwise procedure for isolation of murine bone marrow and generation of dendritic cellsJournal of Biological Methods, 2014
- Platinum nanoparticles for the photothermal treatment of Neuro 2A cancer cellsBiomaterials, 2013
- Cancer immunotherapy comes of ageNature, 2011
- Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonistsJournal of Immunotoxicology, 2009
- Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cellsNature Immunology, 2009
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studiesJournal of Hepatology, 2007
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848Nature Immunology, 2002